Chronic immunoglobulin maintenance therapy in myasthenia gravis.,European Journal of Neurology

当前位置： X-MOL 学术 › Eur. J. Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Chronic immunoglobulin maintenance therapy in myasthenia gravis.
European Journal of Neurology ( IF 4.5 ) Pub Date : 2020-09-22 , DOI: 10.1111/ene.14547
M Alcantara ₁ , E Sarpong ₁ , C Barnett ₁ , H Katzberg ₁ , V Bril ₁

Affiliation

Long‐term treatment of myasthenia gravis (MG) includes symptomatic and course‐modifying therapies that target the immune system. Recently, both intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) have emerged as viable options for chronic therapy, considering the favourable safety–efficacy profile and possible immunosuppressant sparing properties. The aim was to investigate the outcomes of the long‐term care of generalized MG with immunoglobulin (Ig).

中文翻译：

重症肌无力的慢性免疫球蛋白维持治疗。

重症肌无力 (MG) 的长期治疗包括针对免疫系统的对症治疗和改善病程的治疗。最近，考虑到良好的安全性和有效性以及可能的免疫抑制剂保留特性，静脉注射免疫球蛋白 (IVIG) 和皮下免疫球蛋白 (SCIG) 已成为慢性治疗的可行选择。目的是研究免疫球蛋白 (Ig) 对全身性 MG 的长期护理结果。

更新日期：2020-09-22

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11